Lasagna, Louis

 


Title: LOUIS C. LASAGNA PAPERS
Date range: 1947 - 2001
Location: D. 302
Size: 19 boxes and 122 volumes

 

 

 


Louis Cesare Lasagna was an internationally recognized and respected expert in clinical pharmacology. Born in Queens, New York, in 1923, Lasagna was raised in New Brunswick, New Jersey, by his Italian immigrant parents. He graduated from Rutgers University in 1943 and earned his medical degree from Columbia in 1947. After completing a clinical research fellowship in anesthesia at Harvard Medical School, Lasagna joined the faculty of Johns Hopkins University in 1954, where he established the first ever clinical pharmacology department. Lasagna taught medicine and pharmacology at Johns Hopkins until 1970, when he accepted the position as the first chairman of the Department of Pharmacology and Toxicology at the University of Rochester, School of Medicine and Dentistry, which he held for the next decade (1970 -1980). Early in his fourteen year career at Rochester, Lasagna founded the Center for the Study of Drug Development. In July 1984, the Center moved with Lasagna to Tufts University, where he became dean of the Sackler School of Graduate Biomedical Sciences.

While living in Rochester, Lasagna was also active in the city's cultural life, serving as the President of the Rochester Philharmonic Orchestra, supporting the Garth Fagan Dance company, and writing, directing, and starring in the "Mighty Lasagna Players" annual theater production by the University of Rochester, Department of Pharmacology Medical and Toxicology students and faculty.

Throughout Lasagna's distinguished career he wrote and lectured extensively on a variety of topics. He was well-known for his simple eloquence, as well as his sense of humor and humanity in addressing such controversial topics as birth control, abortion, euthanasia, and medical experimentation on humans. In 1964, Lasagna wrote a modernized version of the Hippocratic Oath, which emphasized a holistic and compassionate approach to medicine. Today, the "Lasagna Oath" has been adopted by many medical colleges.

In addition to elucidating medical ethics, Lasagna figured prominently in the conceptualization of controlled clinical trials and the placebo effect. He served as a consultant to, and headed, several Federal commissions on Federal drug approval. Lasagna's work led to the improvement of controlled clinical trials to test drug effectiveness, and improved the regulation of drugs for effectiveness and safety.

In 1962 Lasagna delivered testimony to Congress during the Kefauver hearings on the 1962 amendments to the Food, Drug and Cosmetic Act. His guidance resulted in, among other things, the requirement for controlled clinical trials as necessary for proving drug effectiveness as a condition for regulatory approval of a new drug which resulted in major improvements in the evidentiary standard in the Food and Drug Administration (FDA) and the pharmaceutical industry. This was the first prescription drug law in the world to specify the criteria for proving effectiveness, and caused other countries to follow suit. It may be the largest single advance in the standards and outcome of medical therapy of all time.

Among the subsequent committees that Lasagna served on were: the National Committee to Review Procedures for the Approval of New Cancer and AIDS Drugs, the "blue ribbon" panel to examine the FDA, and the "Rogers Group" aimed at reforming drug regulation processes.

Lasagna's numerous honors and awards include two honorary Sc.D. degrees from Hahnemann Medical School (1980) and Rutgers University (1983); and an honorary doctoral degree from the University of Alcal√° in Spain (1998).

The "father of clinical pharmacology," died in August 2003, survived by his wife Helen, their seven children, Nina, David, Maria, Krissy, Lisa, Peter, and Christopher, and grandchildren.

The original collection consists of 12 boxes containing articles, correspondence, photographs, and other materials, related mostly to Lasagna's medical career, but also to his personal life. The collection retains the chronological order established by Lasagna. Please see the bibliography of short works (in the collection) written by Lasagna, the correspondence table, photograph list, and bibliography of books following the box and folder descriptions for more detailed content descriptions.

Donated by Louis C. Lasagna and the Lasagna family, March 2003.

Lasagna Addition, Boxes 13 -19.

An addition to the Louis Lasagna Papers was acquired in June 2007. It consists of subject files and video tapes. [Contents and order within the subject files has been retained in most instances to preserve the relevance of Lasagna's notes. However, the files are arranged alphabetically by subject.] Materials in the addition are not reflected in the bibliography of short works, correspondence table, or photograph lists of the original register. 

 

 

 



Contents:



BOX1: 1947 – 1959

Folder:
1:1: 1947 - 1949

Letters to and from Lasagna; articles and manuscripts written by Lasagna; and a cast list and partial script for A Chief Complaint, a musical comedy in which Louis Lasagna appeared.

1:2: 1950s

Reprints of articles about clinical trials and drug studies originally published in the 1950s (by other authors) and a memorandum to Solid Tumor Group containing statistics on a 1957 study; arranged chronologically.

1:3: 1950 - 1953

Letters to Lasagna; schedules for lectures given by Lasagna; articles and reprints by Lasagna. Topics include: antidiuretic action and effects; barbiturates; Norpinehrine in Parotid gland secretion; oral analgesics; placebo effect; and Terramycin.

1:4: January -September 1954

Letters to Lasagna; schedules and announcements for speaking engagements given and attended by Lasagna; articles and reprints by Lasagna. Topics include: dead germs; and placebo.

1:5: October - December 1954

Letters to Lasagna; announcements, schedules, programs, etc. for speaking engagements and conferences given or attended by Lasagna; articles and reprints by Lasagna. Topics include: analgesic effectiveness; and Nalorphine.

1:6: January - June 1955

Letters to Lasagna; announcements, schedules, programs, etc. for speaking engagements and conferences given or attended by Lasagna; articles and reprints by Lasagna; reviews of Lasagna's published writing; and articles about Lasagna. Topics include: controlled clinical trial; drug-induced mood changes; and hypnotic potency.

1:7: July - December 1955

Letters to Lasagna; announcements, schedules, programs, etc. for speaking engagements and conferences given or attended by Lasagna; articles and reprints by Lasagna; and articles about Lasagna. Topics include: drug-induced mood changes; placebo.

1:8: January - June 1956

Letters to Lasagna; announcements, schedules, programs, etc. for speaking engagements and conferences given or attended by Lasagna; articles and reprints by Lasagna; and articles about Lasagna. Topics include: hypnotic drugs; placebo, psychology and drugs.

1:9: July - December 1956

Letters to Lasagna; announcements, schedules, programs, etc. for speaking engagements and conferences given or attended by Lasagna; articles and reprints by Lasagna; and articles about Lasagna. Topics include: Baltimore Museum of Art rental gallery; hypnotics; Joseph Lasagna [father]; and pain relief.

1:10: 1957

Letters to Lasagna; announcements, schedules, programs, etc. for speaking engagements and conferences given or attended by Lasagna; articles and reprints by Lasagna; and articles about Lasagna. Topics include: Dr. John Jacob Abel Centenary; hypnotics; and tranquilizers.

1:11: January - June 1958

Letters to Lasagna; announcements, schedules, programs, etc. for speaking engagements and conferences given or attended by Lasagna; articles and reprints by Lasagna; articles about Lasagna; and photographs. Topics include: chemotherapy; Kefauver hearings; and pharmaceutical advertising.

1:12: July - December 1958

Letters to Lasagna; announcements, schedules, programs, etc. for speaking engagements and conferences given or attended by Lasagna; articles and reprints by Lasagna; and articles about Lasagna. Topics include: Baltimore Museum of Art, Sales and Rental Gallery; Dextromoramide; and urinary tract infection.

1:13: 1959

Letters to Lasagna; announcements, schedules, programs, etc. for speaking engagements and conferences given or attended by Lasagna; articles and reprints by Lasagna; and articles about Lasagna. Topics include: Kefauver hearings; and pharmaceutical advertising.


BOX 2: January 1960 - December 1963

Folder:
2:1: January - April 1960

Letters to and from Lasagna; announcements, schedules, programs, etc. for speaking engagements and conferences given or attended by Lasagna; articles and reprints by Lasagna; articles about Lasagna. Topics include: analgesics; arms control; pharmaceutical advertising; nuclear testing; and wonder drugs.

2:2: May - December 1960

Letters to Lasagna; announcements, schedules, programs, etc. for speaking engagements and conferences given or attended by Lasagna; articles and reprints by Lasagna; and articles about Lasagna. Topics include: drug testing; and Lucille de Mandel Witt.

2:3: January -July 1961

Letters to Lasagna; announcements, schedules, programs, etc. for speaking engagements and conferences given or attended by Lasagna; book reviews by Lasagna; articles about Lasagna; articles by other authors; and a radio news release [discussing global political tensions] Topics include: analgesics; arthritis; sleep aids; cyproheptadine; and placebo.

2:4: August - December 1961

Letters to Lasagna; announcements, schedules, programs, etc. for speaking engagements and conferences given or attended by Lasagna; articles and reprints by Lasagna; articles about Lasagna; advertisements for and reviews of Doctors' Dilemma; and an advertisement for Biopharmaceutics [a film report featuring Lasagna]. Topics include: analgesics; drug experimentation on prison inmates; Kefauver hearings; Methotrimeprazine [morphine substitute]; prescription drug prices; and prescription drug research.

2:5: January - February 1962

Letters to Lasagna; announcements, schedules, programs, etc. for speaking engagements and conferences given or attended by Lasagna; articles and reprints by Lasagna; and articles about Lasagna, including reviews of Doctors' Dilemmas. Topics include: American Medical Association; 'drug age' problem; improving the human body; Kefauver hearings; methtrimeprazine [morphine substitute]; and nuclear testing.

2:6: March 1962

Letters to and from Lasagna; announcements, schedules, programs, etc. for speaking engagements and conferences given or attended by Lasagna; articles and reprints by Lasagna; and articles about Lasagna, including reviews of his book, The Doctors' Dilemmas. Topics include: arteriosclerosis and fats; and Kefauver hearings.

2:7: April - June 1962

Letters to and from Lasagna; announcements, schedules, programs, etc. for speaking engagements and conferences given or attended by Lasagna; articles and reprints by Lasagna; articles about Lasagna, including advertisements for and reviews of TheDoctors' Dilemmas; and medical articles by other authors. Topics include: Kefauver hearings.

2:8: July - October 1962

Letters to Lasagna; announcements, schedules, programs, etc. for speaking engagements and conferences given or attended by Lasagna; articles and reprints by Lasagna; and articles about Lasagna, reviews of The Doctors' Dilemmas. Topics include: drug regulation; human experimentation; Kefauver hearings; thalidomide; and the White House Conference on Narcotic and Drug Abuse.

2:9: November - December 1962

Letters to Lasagna; announcements, schedules, programs, etc. for speaking engagements and conferences given or attended by Lasagna; articles and reprints by Lasagna; and articles about Lasagna, reviews of The Doctors' Dilemmas. Topics include: aspirin compounds; Cyanamid pain killers; drug addiction; and thalidomide.

2:10: January - June 1963

Letters to and from Lasagna; announcements, schedules, programs, etc. for speaking engagements and conferences given or attended by Lasagna; articles and reprints by Lasagna; and articles about Lasagna, reviews of The Doctors' Dilemmas. Topics include: aspirin compounds; Bayer aspirin ads; drug use in pregnancy; Federal Trade Commission (FTC); narcotic addiction; nuclear warfare and world disarmament; and thalidomide.

2:11: July - December 1963

Letters to Lasagna; announcements, schedules, programs, etc. for speaking engagements and conferences given or attended by Lasagna; articles and reprints by Lasagna; articles about Lasagna, advertisements for and reviews of The Doctors' Dilemmas; photographs; and “Recommendations On Procedures For The Employment of Investigational Drugs In The John Hopkins Hospital, Submitted By The Pharmacy And Therapeutics Committee,” with blank “Consent To Use Investigational Drugs” forms.  Topics include: clinical trials; drug labels, prices, and regulations; Kefauver hearings; "Lasagna Oath;" norethynodrel (Enovid); nuclear warfare and world disarmament; thalidomide; and toxic drugs.


BOX3: January 1964 - December 1967

Folder:
3:1: January – March 1964

Letters to Lasagna; announcements, programs, etc., for lectures and speaking engagements given by Lasagna; script for “One Man’s Opinion” WBAL-TV; reviews, articles and reprints by Lasagna; articles about Lasagna; conference programs; notes; and patient studies. Topics include: drug trials; the Hippocratic oath; harms of smoking; need for perspective in medicine; and toxicological iceberg.

3:2: April – June 1964

Letters to Lasagna; announcements, schedules, programs, etc. for speaking engagements and conferences given or attended by Lasagna; articles and reprints by Lasagna; and drug studies. Topics include: analgesics; Bayer aspirin advertisements; and the Hippocratic oath.

3:3: July - December 1964

 Letters to and from Lasagna; articles and reprints by Lasagna; articles about Lasagna. Topics include: drug development and testing; the Hippocratic Oath; the Medical Committee for Human Rights; placeboes; and S.A.N.E. (National Committee for a Sane Nuclear Policy).

3:4: January - March 1965

Letters to Lasagna; announcements, schedules, programs, etc. for speaking engagements given by Lasagna; reprints of articles by Lasagna; articles about Lasagna. Topics include: birth control; drug side effects; Federal Drug Administration (FDA); Federal Trade Commission (FTC); and S.A.N.E. (National Committee for a Sane Nuclear Policy).

3:5: April - September 1965

Letters to Lasagna, announcements, schedules, programs etc. for speaking engagements given and conferences attended by Lasagna; reprints of articles by Lasagna; articles about Lasagna; and photographs. Topics include: the Eighth Annual Medical Progress Assembly and Lasagna's book The Doctors' Dilemmas.

3:6: October - December 1965

Letters to and from Lasagna; announcements, schedules, programs, etc. for speaking engagements given and conferences attended by Lasagna; including the White House Conferences on Health and International Cooperation; reprints and articles by Lasagna; and articles about Lasagna. Topics include: birth control; John Hopkins Medical History Club; and Sarsaparilla Restorative.

3:7: January - July 1966

Letters to Lasagna; announcements, schedules, programs, etc. for speaking engagements given and conferences attended by Lasagna; reprints and articles by Lasagna; articles about Lasagna; and photographs. Topics include: birth control; brain oxygenation in stroke patients; FDA regulations; Iatrogenic Disorders; sleeping pills; and training for doctors.

3:8: August - December 1966

Letters to Lasagna; announcements, schedules, programs, etc. for speaking engagements given and conferences attended by Lasagna; reprints and articles by Lasagna; articles about Lasagna. Topics include: drug abuse; hypnotic drugs; medical ethics and research; and therapeutics.

3:9: January - May 1967

Letters to and from Lasagna; announcements, schedules, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles and reprints by Lasagna; articles about Lasagna, including a review of International Encyclopedia of Pharmacology and Therapeutics. Section 6, Vol. I & II: Clinical Pharmacology, edited by Lasagna, and an interview with Lasagna in Medical World News; and drug trial reprints. Topics include: drug consent rules; Indomethacin; pediatrics; and placebo.

3:10: June - December 1967

Letters to Lasagna; announcements, schedules, programs, etc. for speaking engagements given and conferences attended by Lasagna; reprints of articles by Lasagna; articles about Lasagna, including a review of International Encyclopedia of Pharmacology and Therapeutics. Section 6, Vol. I & II: Clinical Pharmacology, edited by Lasagna; and photographs. Topics include: alumni honored at the Centennial Convocation of New Brunswick High School; birth control; Federal Trade Commission; 46th South African Medical Congress; and World Health Organization.


BOX4: January 1968 - December 1969

Folder:
4:1: January - June 1968

Letters to and from Lasagna; announcements, schedules, programs, etc. from speaking engagements given and conferences attended by Lasagna; reprints and articles by Lasagna; advertisements and reviews of Lasagna's book Life, Death, and the Doctor; photographs; and reprints and articles by other authors. Topics include: drug abuse; drug control; and Life, Death, and the Doctor.

4:2: July - September 1968

Letters to Lasagna; announcements, schedules, programs, etc. for speaking engagements given and conferences attended by Lasagna; advertisements for and reviews of Life, Death, and the Doctor; and photographs. Topics include: birth control; prescription drugs; Life, Death, and the Doctor, and the World Health Organization.

4:3: October - December 1968

Letters to and from Lasagna; announcements, schedules, programs, etc. for speaking engagements given and conferences attended by Lasagna; reprints and articles by Lasagna; reviews of Life, Death, and the Doctor; articles about Lasagna; and photographs. Topics include: birth control; drug abuse; Life, Death, and the Doctor; "Doctor and Society" teaching series, and the World Health Organization.

4:4: January - March 1969

Letters to Lasagna; announcements, schedules, programs, etc. for speaking engagements given and conferences attended by Lasagna; reprints and articles by Lasagna; reviews of Life, Death, and the Doctor; and articles about Lasagna. Topics include: amphetamines; analgesics; birth control; fatality; Federal Drug Administration; and pain killers.

4:5: April - May 1969

Letters to Lasagna; announcements, schedules, programs, etc. for speaking engagements given and conferences attended by Lasagna; Lasagna testimony before the House committee on interstate and foreign commerce on cigarette labeling; articles by Lasagna; reviews of Life, Death, and the Doctor; articles about Lasagna. Topics include: amphetamines; birth control; "Doctor and Society" teaching series; the Federal Drug Administration; and Maryland politics.

4:6: June - August 1969

Letters to Lasagna; announcements, schedules, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles by Lasagna; articles about Lasagna; and medical articles by others. Topics include: diet and the heart; drug consent rules; and the hazards of smoking.

4:7: September - December 1969

Letters to and from Lasagna; announcements, schedules, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles and reprints by Lasagna; articles about Lasagna; and medical articles by others. Topics include: birth control; cyclamates; Lasagna's appointment to the University of Rochester Pharmacology Department; organ donation; Panalba; and the World Health Organization.


BOX5: January 1970 - April 1973

Folder:
5:1: January - March 1970

Letters to Lasagna; announcements, schedules, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles and reprints by Lasagna; articles about Lasagna; press releases; and photographs. Topics include: birth control; and Lasagna's appointment to the University of Rochester Pharmacology Department.

5:2: April - June 1970

Letters to and from Lasagna; announcements, schedules, programs, scripts, etc. for speaking engagements given and conferences attended by Lasagna; articles and reprints by Lasagna; articles about Lasagna; press releases; inventory of office equipment; and medical articles by other authors. Topics include: dying; The Doctor's Dilemmas; Lasagna's appointment to the University of Rochester Pharmacology Department; and pain.

5:3: July - December 1970

Letters to Lasagna; announcements, schedules, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles and reprints by Lasagna; articles about Lasagna; press releases. Topics include: coronary drugs, the elderly, national health insurance, teaching, terminal illness, and the World Health Organization.

5:4: January - April 1971

Letters to Lasagna; announcements, schedules, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles and reprints by Lasagna; articles about Lasagna; press releases; and articles by other authors. Topics include: antibiotics; drug abuse; and headache treatment.

5:5: May - August 1971

Letters to Lasagna; announcements, schedules, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles and reprints by Lasagna; articles about Lasagna. Topics include: diabetes.

5:6: September - December 1971

Letters to Lasagna; announcements, schedules, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles and reprints by Lasagna; articles about Lasagna; press releases; and medical articles by other authors. Topics include: the National Academy of Sciences; and the World Health Organization.

5:7: January - March 1972

Announcements, schedules, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles and reprints by Lasagna; articles about Lasagna, including reviews of Lasagna's publications; press releases; and Lasagna's "Outstanding Educators of America" award. Topics include: the Food and Drug Administration; and Lasagna's appointment to the faculty of SUNY School of Pharmacy.

5:8: April - June 1972

Letters to Lasagna; announcements, schedules, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles and reprints by Lasagna; articles about Lasagna; press releases; and medical articles by other authors. Topics Include: cardiac transplant; diet pills; the Food and Drug Administration; Monogloid infants; the rights of the disabled; and tuberculosis.

5:9: July - December 1972

Announcements, schedules, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles and reprints by Lasagna; articles about Lasagna; and medical articles by other authors. Topics include: death and dying; diet pills; the Food and Drug Administration; lung cancer; prescription drug follow-up; subarachnoid hemorrhage and ruptured aneurysms.

5:10: January - April 1973

Letters to Lasagna; announcements, schedules, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles and reprints by Lasagna; articles about Lasagna; and a song written and performed by Lasagna by his staff in honor of his 50th Birthday. Topics include: Award for Distinguished Achievement (Modern Medicine); euthanasia; insomnia medication; and Lasagna's 50th birthday celebration.


BOX 6: May 1973 - June 1975

Folder:
6:1: May - August 1973

Letters to Lasagna; announcements, schedules, programs etc. for speaking engagements given and conference attended by Lasagna; articles and reprints by Lasagna; articles about Lasagna; China Exchange newsletters (Spring 1973 and Summer-Fall 1973); and PARCOST Comparative Drug Index, Ministry of Health, May 1973. Topics include: appetite suppressants; and euthanasia.

6:2: September - December 1973

Letters to Lasagna; announcements, schedules, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles and reprints by Lasagna; articles about Lasagna; and medical articles by other authors. Topics include: controlled trials; drug lag; euthanasia; generic vs. brand-name drugs; hypnotics; and medical ethics.

6:3: January - April 1974

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles and reprints by Lasagna; articles about Lasagna; photographs; and medical articles by other authors. Topics include: acupuncture; Food and Drug Administration; prescription labels; and rights of the disabled.

6:4: May - June 1974

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; and articles about Lasagna. Topics include: the Herbal Pharmacology Study Group to the People's Republic of China.

6:5: May - June 1974

Lasagna's China diary; and scripts and notes for talks delivered on Chinese medicine and his experience in China.

6:6: July - December 1974

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles and reprints by Lasagna; articles about Lasagna; newsletters; and medical articles by other authors. Topics include: the Academy of Pharmaceutical Sciences; and the Herbal Pharmacology Study Group to the People's Republic of China.

6:7: January - March 1975

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles and reprints by Lasagna; articles about Lasagna; review of Lasagna's book The VD Epidemic; and press releases. Topics include: adverse drug reactions; birth control; euthanasia; human experimentation; and the Oscar B. Hunter Award.

6:8: April - June 1975

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles and reprints by Lasagna; articles about Lasagna, including reviews of his published works; and photographs. Topics include: the Food and Drug Administration; placebo; and the University of Rochester pharmacology department production of "The Oz Connection."


Box7: July 1975 - December 1977

Folder:
7:1: July - October 1975

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles and reprints by Lasagna; articles about Lasagna, including reviews of his published works; and photographs. Topics include: Chinese medicine; Food and Drug Administration; Rochester Philharmonic Orchestra; sleep aids and tranquilizers; and the VD epidemic.

7:2: November - December 1975

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles and reprints by Lasagna; articles about Lasagna, including two interviews; and photographs. Topics include: the common cold; role of the doctor; sleeping aids; and VD.

7:3: January - March 1976

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles by Lasagna; articles about Lasagna; and photographs. Topics include: the common cold; and the Roche award.

7:4: April - July 1976

Letters to and from Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna, including his introduction to Margaret Mead; articles by Lasagna; and articles about Lasagna; and photographs. Topics include: ASPET award; Henry K. Beecher; Margaret Mead; and the University of Rochester pharmacology department production of "Star Dreck."

7:5: August - October 1976

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles and reprints by Lasagna; articles about Lasagna. Topics include: Howard Hanson; and the Rochester Philharmonic Orchestra.

7:6: November - December 1976

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles and reprints by Lasagna; articles about Lasagna; and photographs. Topics include: amphetamines; antibiotics and the common cold; the Food and Drugs Administration; elective hysterectomy; the rights of the unborn, children, and retarded; and smallpox.

7:7: January - March 1977

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles by Lasagna; and articles about Lasagna. Topics include: adverse drug reactions; and human experimentation.

7:8: April - May 1977

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles and reprints by Lasagna; articles about Lasagna; and medical articles by other authors. Topics include: Food and Drug Administration; Ginseng; human experimentation; methadone and alcohol mixing; Rochester Philharmonic Orchestra; and terminal care.

7:9: June - September 1977

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles and reprints by Lasagna; and medical articles by other authors. Topics include: the Hippocratic Oath; human experimentation; and the Rochester Philharmonic Orchestra.

7:10: October - December 1977

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles by Lasagna; articles about Lasagna; and medical articles by other authors. Topics include: massage and pain relief; and self-prescription of medication.


BOX8: January 1978 - December 1981

Folder:
8:1: January - April 1978

Letters to and from Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles and reprints by Lasagna; articles about Lasagna; and press releases. Topics include: American College of Neuropsychopharmacology; state substitution laws.

8:2: May - June 1978

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles and reprints by Lasagna; and articles about Lasagna, including reviews of his published works. Topics include: state substitution laws; and the University of Rochester pharmacology department production of "The Phunny Pharm Awards."

8:3: July 1978- September 1978

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles and reprints by Lasagna; articles about Lasagna; and photographs. Topics include: the Food and Drug Administration; and the Rochester Philharmonic Orchestra.

8:4: October - December 1978

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna, including a speech in honor of his secretary Kris Wemett; articles by Lasagna; and articles about Lasagna. Topics include: amphetamines; drug testing regulations; and the Rochester Philharmonic Orchestra.

8:5: January 1979- March 1980

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles and reprints by Lasagna; articles about Lasagna; and photographs. Topics include: the Food and Drug Administration; and the Rochester Philharmonic Orchestra.

8:6: April - May 1980

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna, including program from the University of Rochester pharmacology department production of "Now That's Incredible!!!"; articles and reprints by Lasagna; articles about Lasagna; and photographs. Topics include: FDA drug approval; human rights and medical research; and obesity.

8:7: June - July 1980

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna, including the Festschrift held in Lasagna's honor; articles and reprints by Lasagna; articles about Lasagna; and photographs. Topics include: drug lag; and Honorary Degree Citation awarded to Lasagna.

8:8: August - December 1980

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles and reprints by Lasagna; articles about Lasagna, including review of his published works; and medical articles by other authors. Topics include: honors bestowed on Lasagna.

8:9: January - May 1981

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles and reprints by Lasagna; reviews of his published works.

8:10: June - August 1981

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles about Lasagna; and photographs. Topics include: International Conference of Nutrition, June 6-9 , 1981.

8:11: September - December 1981

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles and reprints by Lasagna; articles about Lasagna, including reviews of Controversies in Internal Medicine, ed. F. J. Ingelfinger; certificates from the Environmental Protection Agency and the University of Rochester; photographs; and medical articles by other authors. Topics Include: birth control; drug abuse; the Food and Drug Administration; Garth Fagan Dance; and terminal illness and pain control.


BOX9: January 1982 - December 1984

Folder:
9:1: January - March 1982

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles and reprints by Lasagna; articles about Lasagna; photographs; and press releases. Topics include: Triazolam; and weight loss.

9:2: April - August 1982

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles and reprints by Lasagna; articles about Lasagna; and photographs. Topics include: antidepressant drugs; aspirin; human experimentation; marijuana; and University of Rochester pharmacology department production of "Elmwood Avenue Blues."

9:3: September - December 1982

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles and reprints by Lasagna; articles about Lasagna, including reviews of Lasagna's published works; and photographs. Topics include: cigarettes; Garth Fagan Dance; generic drugs; human rights; and Tylenol.

9:4: January - May 1983

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles and reprints by Lasagna; articles about Lasagna, including reviews of Lasagna's published works. Topics include: Christopher Lasagna [son] conducting the Brighton Symphony Orchestra; drug use in the U.S. military; honorary degree, Rutgers University; and Loyal Sons of Rutgers award.

9:5: June - July 1983

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles and reprints by Lasagna; articles about Lasagna; and photographs. Topics include: honorary degree, Rutgers University; and naming of the Chinese president, Li Xianmian.

9:6: August - September 1983

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles and reprints by Lasagna; articles about Lasagna. Topics include: Christopher Lasagna [son] conducting the Brighton Symphony Orchestra; honorary degree, Rutgers University; and ibuprofen.

9:7: October - December 1983

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles and reprints by Lasagna; articles about Lasagna, photographs. Topics include: ibuprofen.

9:8: January - March 1984

Letters to and from Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles by Lasagna; and articles about Lasagna. Topics include: Lasagna's acceptance of position as dean at Tufts; and marijuana.

9:9: April - June 1984

Letters to and from Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles by Lasagna; articles about Lasagna; and photographs. Topics include: insomnia; Joseph Lasagna [father]; and the University Rochester Medical Student production "AFTER*G*A*S*H."

9:10: July - December 1984

Letters to and from Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; poem by Lasagna; articles about Lasagna; and photographs. Topics include: Joseph Lasagna [father]; and Louis Lasagna's acceptance of position at Tufts.


BOX10: January 1985 - December 1988

Folder:
10:1: January - December 1985

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles and reprints by Lasagna; articles about Lasagna; and photographs. Topics include: Sterling Visiting Professorship grant given to Tufts in Lasagna's honor.

10:2: January - April 1986

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles about Lasagna; and photographs. Topics include: Garth Fagan Dance; and Sterling Visiting Professorship.

10:3: May - September 1986

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles by Lasagna; articles about Lasagna; and photographs. Topics include: revisions to the Hippocratic Oath, including Lasagna's Oath.

10:4: October - December 1986

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; and articles about Lasagna. Topics include: "The Lasagna Oath," orphan drugs, and the Vatican conference on drugs.

10:5: January - April 1987

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles about Lasagna; photographs , and "Felix Dies Natalis" birthday banner (see photographs). Topics include: ethics and morality in medicine.

10:6: May - September 1987

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; article by Lasagna in Japanese edition of Journal of American Medical Association; articles about Lasagna; and photographs. Topics include: Hippocratic and Lasagna oaths.

10:7: October - December 1987

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna, including remarks made at Arthur M. Sackler Memorial Service; articles about Lasagna. Topics include: Hippocratic and Lasagna oaths.

10:8: January - December 1988

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles by Lasagna; articles about Lasagna; and photographs. Topics include: Louis Lasagna's 65th birthday.


BOX 11: January 1989- December 1991

Folder:
11:1: January - April 1989

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles about Lasagna; and photographs. Topics include: AIDS, death of Lasagna's father, Joseph Lasagna; the Food and Drug Administration; and patient rights.

11:2: May - September 1989

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; Louis Lasagna's testimony before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce of the United States House of Representatives; articles about Lasagna, including reviews of his published works; and photographs. Topics include: AIDS drugs; cancer drugs; the Food and Drug Administration; the "Lasagna Committee;" and the MIT/TUFTS "Cell Paper" research fraud.

11:3: October - December 1989

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles by Lasagna; and articles about Lasagna. Topics include: cancer drugs; and the "Lasagna Committee."

11:4: January - March 1990

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles by Lasagna; articles about Lasagna; press releases and photographs. Topics include: the Food and Drug Administration; and the blue ribbon commission.

11:5: April - June 1990

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conference attended by Lasagna; articles by Lasagna; articles about Lasagna; and photographs. Topics include: cost of drug development; and the Hippocratic Oath.

11:6: July - December 1990

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles by Lasagna; articles about Lasagna; and photographs. Topics Include: AIDS; cancer; and the "Lasagna Committee."

11:7: January - April 1991

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles about Lasagna; and press releases. Topics include: AIDS, the Food and Drug Administration; and secondhand smoke.

11:8: May - August 1991

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles written by Lasagna; articles about Lasagna; a certificate awarded to Lasagna; and photographs. Topics include: Hippocratic Oath; and "Cancer, AIDS and Society."

11:9: September - December 1991

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles by Lasagna; articles about Lasagna; and a certificate awarded to Lasagna. Topics include: the Hippocratic oath; the Lasagna oath; and the Professor Louis Lasagna Educational Complex (Israel).


BOX 12: January 1991 - December 1994

Folder:
12:1: January - April 1992

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; Congressional Certificate of Merit awarded to Lasagna; and photographs.

12:2: May - August 1992

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; certificates awarded to Lasagna; press releases; and photographs. Topics include: the "inauguration" of the Prof. Louis Lasagna Educational Complex.

12:3: September - December 1992

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles written by Lasagna; articles about Lasagna; and photographs. Topics include: research fraud.

12:4: January - April 1993

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles written by Lasagna; articles about Lasagna; and photographs. Topics include: Center for the Study of Drug Development.

12:5: May - July 1993

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; photographs; and medical articles written by other authors. Topics include: cancer; and industrial chemicals and environmental hazards.

12:6: August - December 1993

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles by Lasagna; articles about Lasagna, including: an advertisement for The Scientist, and a certificate awarded to Lasagna, reviews of Lasagna's published works; a certificate awarded to Lasagna; and photographs . Topics include: human research and experimentation; J. Allyn Taylor International Prize; and the Rutgers' Medal.

12:7: January - March 1994

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles about Lasagna; photographs. Topics include: Distinguished Professorship, Tufts University; and the quantification of pain.

12:8: April - December 1994

Letters to Lasagna; announcements, programs, etc. for speaking engagements given and conferences attended by Lasagna; articles by Lasagna; articles about Lasagna; certificates awarded to Lasagna; and photographs. Topics include: Distinguished Professorship, Tufts University.

12:9: undated, controlled trials

Outlines, notes, and essays on controlled trials, not dated.


BOX 13: Agonist-Antagonist Analgesics; "Blitz" / "Hoecht-Roussell Seminar, Buck Hill Falls, PA., September 26, 1979;" Clinical Trials; and Commercialization of the Molecule.

Folder:

Agonist-Antagonist Analgesics

13:1 Lasagna. "Benefit-Risk Ratio of Agonist-Antagonist Analgesics," MS and notes, n.d.

13:2 Lasagna. "Benefit-Risk Ratio of Agonist-Antagonist Analgesics," three TS, August 1986 and n.d.

13:3 Lasagna. "Benefit-Risk Ratio of Agonist-Antagonist Analgesics," reprint from Drug and Alcohol Dependence, 20 (1987), pg. 385-393.

13:4 Related correspondence:

 

  • Lasagna to Juliette Sawe, TS, August 7, 1986.
  • Lasagna to Tomoji Yanagita, TS, August 7, 1986.
  • [attached to above] Tomoji Yanagita to Lasagna, TS, May 14, 1986.
  • from editor of Drug and Alcohol Dependence, with attachments, November 6, 1987.
  • from Tomoji Yanagita, TS, February 12, 1998.


"Blitz" / "Hoecht-Roussell Seminar, Buck Hill Falls, PA., September 26, 1979"

13:5 Lasagna. "How Much Regulation Is Desirable In Industry?" TS, n.d.

  • also, [Lasagna?] "The Evolution of Clinical Trials," TS with MS editing, n.d.; and "Table VII 'The Normal Volunteer

 


13:6 Articles, Studies, and MS notes:

 

  • Peylan-Ramu, Nili, et al. "Abnormal CT Scans Of The Brain In Asymptomatic Children With Acute Lymphocytic Leukemia After Prophylactic Treatment Of The Central Nervous System With Radiation And Intrathecal Chemotherapy," New England Journal of Medicine, April 13, 1978, pgs. 815 - 818.
  • Wald, Arnold, et al. "Non-Antibiotic-Associated Pseudomembranous Colitis Due to Toxin-Producing Clostridia," Annals Of Internal Medicine, 92:6, pgs. 798 -799.
  • [author unidentified] "Demands For More Animal Tests Have Cut R&D Productivity," April5, 1980, pg. 2, PC.
  • Gori, Gio Batta. "The Regulation of Carcinogenic Hazards," Science, 218:18, April 18, 1980, PGS. 256 - 262.
  • George, C.F. et. al. "Can Adverse Drug Reactions Be Prevented?" Adverse Drug Reactions Bulletin, No. 80, February 1980, pg. 288 - 291.
  • [author unidentified] "Clinical Trial Certificates" and "Association Of The British Pharmaceutical Industry," The Lancet, April 26, 1980, pg. 941, PC.
  • [Report of a European Workshop held in Sestri Levante, Italy, September 28-30, 1976]. "Towards a More Rational Regulation of the Development of New Medicines," European Journal of Clinical Pharmacology, 1977, pg. 233- 238.
  • [author unidentified] "Injuries in Research: What Sort of Compensation?" The Lancet, June 28, 1980, pg. 1394 -1395.
  • Goldman, Peter. "Metronidazole: Proven Benefits and Potential Risks," The Johns Hopkins Medical Journal, Vol. 147, 1980, pgs. 1-9.
  • ["The Blue Sheet"] "Clinical Trials on Cataract Extraction Asked," n.d.
  • [editorial by Michael M. Shanin, Rochester, NY]. "R&D Expenditures in the United States," Science, Vol. 200, June 23, 1978, [2 pgs.].
  • Zbinden, G., and M. Flury-Roversi. "Significance of the LD50- Test for the Toxicological Evaluation of Chemical Substances," Archives of Toxicology, Vol. 47 1981, pgs. 77-99.
  • Riester, Elaine Fehr, et. al. "Antipyrine metabolism During the Menstrual Cycle," Clinical Pharmacology and Therapeutics, September 1980, pgs. 384 - 391, PC.
  • "Wardell, William. et. al. "Postmarketing Surveillance of New Drugs," The Journal of Clinical Pharmacology, April 1979, pgs. 169 - 184; [open to pg. 175].
  • "Medico-Pharmaceutical Forum," [Report by the Working Party on Clinical Trials], October 1974, 29 pgs.
  • Healy, J.B. "Nought Outrules Three," [source unidentified, n.d.], pg. 1129.
  • Lasagna, MS notes.
  • Zaffaroni, Alejandro. "Health Horizons What Can Industry Contribute To Future Developments?" [paper presented at the Annual Meeting of the International Federation of Pharmaceutical Manufacturers Association, Hotel El Camino Real, Mexico City, October 31, 1974], TS with illustrations, 22 pgs.
  • Lasagna, MS notes.
  • Roberts, et al. "An Empirical Demonstration of Berkson's Bias," Journal of Chronic Diseases, vol 31, n.d., pg, 119 - 128, PC.
  • Lasagna, MS notes.
  • Enrick, Norbert Lloyd. "The Null Hypothesis - Its Potentials and Pitfalls in Medicine," Hospital Tribune, August 7, 1972.
  • Clark, C.J. and Colin C. Downie. "A Method For The Rapid Determination of the Number of Patients To Include In A Controlled Clinical Trial," The Lancet, December 17, 1988, pg. 1357-1358.
  • Lussier, Andre, et al. "Naproxen: A Novel Approach To Dose-Finding Efficacy Trials In Rheumatoid Arthritis," [reprint from] Clinical Pharmacology And Therapeutics, 14:3, pgs. 434-441, May-June 1973; [ inscribed to Lasagna by author Eugene Segre].
  • Wittenborn, J.R., ed. "Guidelines For Clinical Trials of Psychotropic Drugs," [reprint from] Pharmakopsychiatrie Neuro-Psychopharmakologie, June 1, 1977, pgs 205 - 231].

    [inserted on pgs. 214-215]:

    1. Weiner, Murray. "The Clinical Significance of Drug Efficacy Studies," [Journal of American Medical Society ?], PC.
    2. Bunde, C.A. an H.M. Leyland. "A Controlled Retrospective Survey In Evaluation of Teratogenicity, "July - August 1965, pg. 193 - 198.
    3. Correspondence, John A, Owen, Jr. and Louis Lasagna, TS, April 1966, [2 letters].
    4. Gehan, Edmund A. and Emil J. Freireich. "Non-Randomized Controls In Cancer Clinical Trials," The New England Journal of Medicine, January 24, 1974, pgs. 198 - 204.
    5. Byar, David P. et al. "Randomized Clinical Trials," The New England Journal of Medicine, July 8, 1976, pg. 73 - 80.
    6. Bigelow, Jacob, "The Controlled Clinical Trial With Statistical Assessment - 1835," Annals of Internal Medicine, 85:6, December 1976, pg. 730.
  • Noguchi, Shiro. "Implications of The Statement: No Side Effects Were Observed," The New England Journal of Medicine, February 13, 1975, pg. 372 - 374 [ includes additional articles].
  • Lasagna, MS notes.
  • pg. 164 from Medical Observations, with MS notes [describes a bowel treatment], P
  • medical preparations, ingredient lists, [source unidentified, 2 pgs], PC.

 


13:7 Articles, studies, and MS notes (continued):

 

  • Horwitz, Ralph I. and Alvan R, Feinstein. "Improved Observational Method for Studying Therapeutic Efficacy: Suggestive Evidence That Lidocaine Prophylaxis Prevents Death in Acute Myocardial Infarction," Journal of American Medical Association, 246:21, November 27, 1981., pg. 2455 - 2460.
  • Calimlim, Jose F. and Michael Weintraub. "Selection of Patients participating in A Clinical Trial," [School of Medicine and Dentistry University of Rochester; source unidentified], pg. 107 - 137, PC.
  • Hoft, Richard H. et al. "Halothane Hepatitis in three pairs of Closely Related Women," The New England Journal of Medicine, 304:17, April 23, 1981, pg. 1023 - 1024.
  • Desilva, Regis A., et al. "Lidocaine Prophylaxis in Acute Myocardial Infarction: An Evaluation of Randomised Trials," The Lancet October 17, 1981, Pg. 855 - 858.
  • Reed, James F. III and William Slaichert, Archives of Internal Medicine, Vol 141, September 1981, pg. 1307 - 1310.
  • Quitkin, Frederic M. and Judith G. Rabkin. "Methodological Problems in Studies of Depressive Disorder: Utility of the Discontinuation Design," Journal of Clinical Psychopharmacology, 1:5, 1981, pgs. 283 - 288.
  • Stanley Schor. "Statistical Proof in Inconclusive 'Negative' Trials," Archives of Internal Medicine, 141:10, September 1981, pg. 1263.
  • [various authors] "Correspondence," The New England Journal of Medicine, June 25, 1981, pgs. 1604 - 1606.
  • Horwitz, Ralph I. et al. "Alternative Data Sources And Discrepant Results In Case-Control Studies of Estrogens and Endometrial Cancer," American Journal of Epidemiology, 111:4, pgs. 389 - 394.
  • Wallin, Johan and Jan Sjovall. "Detection of Adverse Drug Reactions in a Clinical Trial Using Two Types if Questioning," Clinical Therapeutics, 3:6, 1981, pg. 450 - 452.
  • [Editorials] "Studies to Compare Treatment Regimens: The Randomized Clinical Trial and Alternative Strategies," (Susan S. Ellenburg); "Lidocaine: Antiarrhythmic Panacea or Cardiac Cosmetic Agent?" (Bernard Lown); and "Diphyllobothriasis" (William R. Barclay), Journal of American Medical Association, 246:21, November 27, 1981, pgs. 2481 - 2483.
  • Cowan, Dale H. "Scientific Design, Ethics and Monitoring: IRB Review of Randomized Clinical Trials," IRB: A Review of Human Subject Research, 2:9, November 1980, pgs. 1- 4.
  • "Vasodilators For Angina Pectoris," Vol 19:10, May 8, 1981; pg 31-40.
  • Sloth, Carl. "Informed Consent," The Lancet, July 4, 1981, pg. 45-46.
  • McClain, Craig J. "Effect of Sorbitol on Psychomotor Function: Its Use in Alcoholic Cirrhosis," Archives of Internal Medicine, Vol 141, June 1981, pg. 901 -903.
  • Conn, Harold O. "Blindness Induced by Double-blindness," Archives of Internal Medicine, Vol 141, June 1981, pg. 846 - 848.
  • Cassileth, Barrie R., et al. "Attitudes Toward Clinical Trials Among Patients and the Public," Journal of American Medical Association, 248:8, August 27, 1982, pg. 968 - 969.
  • Lipsett, Mortimer B. "On the Nature and Ethics of Phase I Clinical Trials of Cancer Chemotherapies," The Journal of the American Medical Association, 248:8, August 27, 1982, pg. 941 -942.
  • [typescripts in Folder 13:5 were moved from this place in original subject folder]
  • Sun, Marjorie. "Depo-Provera Revs Up at FDA: Claims of Cancer Risk With Contraceptive Pose Tough, Nagging Problems for FDA, the State Department, and Third World Countries," Science, Vol 217, July 30, 1982, pgs. 424 - 428.
  • [articles on effects of drugs myocardial infarction] The New England Journal of Medicine, May 13, 1982, pgs. 1168 - 1170, 1121-1134.
  • Harkness, J.A.L., et al. "Circadian Variation in Disease Activity in Rheumatoid Arthritis," British Medical Journal, Vol 284, February 20, 1982.
  • Hayden, Gregory F. et al. "The Case-Control Study: A Practical Review for the Clinician," Journal of American Medical Association. 247:3, January 15, 1982, pg. 326 - 334.
  • Ricardo-Campbell, Rita. et al. "Preliminary Methodology for Controlled Cost-Benefit Study of Drug Impact: The Effects of Cimetidine on Days of Work Lost in a Short-Term Trial in Duodenal Ulcer," Journal of Clinical Gastroenterology 2, 1980, pgs. 37 - 41.
  • Adverse Drug Reactions in The United States, Medicine In the Public Interest [Lasagna was a board member], n.d. 28 pgs.
  • ["Annotations"] "The Limitations of the Randomized Clinical Trial," (Emil J. Freireich and Edmund A. Gehan), IRB: A review of Human Subjects Research, August/ September 1979, pg. 11.
  • [author unidentified] "An Account of the Introduction of Foxglove Into Modern Medicine", [source unidentified, n.d.] pgs. X, 180, 185, 1, 2, PC with MS notes.

 


13:8 "Labels," diagrams [ Note: folded and taped]

Clinical Trials:

13:9 Clinical Report Form, Flexeril Clinical Surveillance Program, July 11, 1977

13:10 Articles by Lasagna:

 

  • "The Evolution of Clinical Trials," TS with MS editing, n.d.
  • "Historical Controls: The Practitioner's Clinical Trials," [reprint from] New England Journal of Medicine, November 18, 1982.

 


13:11 Description of "Lasagna's Law" from Initial Preparation For Clinical Trials, [publisher unidentified, n.d.], pg. 43 - 44, PC, MS content and PC, with MS notes.

13:12 Calimlim, Jose F. and Michael Weintraub."Selection of Patients Participating in A Clinical Trial," [School of Medicine and Dentistry University of Rochester] pg. 107 - 138, PC.

13:13 Fanchaps, Albert. The Testing of Drugs in Man: Justification, Prerequisites, Methods, Problems. Pharma Information, 1984.

13:14 Articles by others [arranged alphabetically by last name of author]:

 

  • Abrams, William B. "Introducing a New Drug into Clinical Practice," [reprint from] Anesthesiology, 35:2, August 1971.
  • Angell, Marcia. "Patients' Preferences In Randomized Clinical Trials," [editorial] The New England Journal of Medicine, May 24, 1984, pg. 1385 - 1388.
  • Avery, Charles W., with Bertram P. Ibelle, Betty Allison, and Nancy Mandell."Systematic Errors in the Evaluation of Side Effects," American Journal of Psychiatry, 123:7, January 7, 1967, pgs. 875 -878, PC.
  • Ciccolunghi, Sheila N., and Hilary A. Chaudri. "A Methodological Study of Some Factors Influencing the Reporting of Symptoms," The Journal of Clinical Pharmacology, 15:4, 1977, pgs. 496 - 505, PC.
  • Downing, R.W. and K. Rickels, and F. Meyers. "Side Reactions in Neurotics: I.A. Comparison of Two Methods of Assessment," The Journal of Clinical Pharmacology, pgs. 289 - 297, PC.
  • Feinstien, Alvan R. and Ralph I. Horwitz. "Double Standards, Scientific Methods, and Epidemiologic Research," The New England Journal of Medicine, 307:26, pg. 1611-1617.
  • Friedman, Gary D. "Experience in Monitoring Drug Reactions in Outpatients: The Kaiser-Permanente Drug Monitoring System," The Journal of the American Medical Association, 217:5, August 2, 1971, pgs. 567 - 572, PC.
  • Gagon, Marc-Andre. "Subjective Phenomena In Drug Trials," International Journal Clinical Pharmacology, 1977, 155-160, PC.
  • Gardner, Pierce, and L. Jeannine Watson. "Adverse Drug Reactions: A Pharmacist-Based Monitoring System," Clinical Pharmacology and Therapeutics, pgs.802 - 807, PC.
  • Green, D.M. "Pre-existing Conditions, Placebo Reactions, and 'Side Effects,'" Annals of Internal Medicine, pgs. 255 - 265, PC.
  • Kupfer, David J., and Thomas P. Detre. "Once More - One the Extraordinary Side Effects of Drugs," Cultural Pharmacology & Therapeutics, 1971, pgs. 575 -582, PC.
  • Lawson, D.H. and D.A. Henry. "Monitoring Adverse Reactions to New Drugs: 'Restricted Release' or 'Monitoring Release'?," British Medical Journal, March 12, 1977, PC.
  • Naranjo, C.A., et al."A Method For Estimating the Probability of Adverse Drug Reactions," Clinical Pharmacology and Therapeutics, August 1981, pg. 239 - 245, PC.
  • Reed, James F. and William Slaichert. "Statistical Proof in Inconclusive 'Negative' Trials," Archives Internal Medicine, Vol 141, September 1981, pgs. 1307 - 1310.
  • Rickels, K. and R.W. Downing. "Side Reactions in Neurotics: II Can Patients Judge Which Symptoms are Caused by Their Medication?" The Journal of Clinical Pharmacology, pg. 298 - 305, PC.
  • Schor, Stanley. "Statistical Proof in Inconclusive 'Negative' Trials," Archives of Internal Medicine, Vol 141, September 1981, pg. 1263 - 1264, PC.
  • Spriet A., et al. "Methodology and Results of a Survey of Adverse Reactions to a Drug in Private Practice," European Journal of Clinical Pharmacology, 1977, pg. 181 - 192, OC with MS notes.
  • [author unidentified]. "Review of Clinical Studies Suggests Many Trials Don't Last Long Enough," Journal of the American Medical Association, 238:2, July 11, 1977, pg. 107-108.
  • Toogood, J.H. "What Do We Mean by 'Usually?'" The Lancet, May 17, 1980.


Commercialization of the Molecule:

13:15 Lasagna. "The Biological Revolution: Commercialization of the Molecule," TS with MS editing, May 1987.

13:16 Lasagna. "The Biological Revolution: Commercialization of the Molecule," TS, 4 copies with attached correspondence, June 1987.

13:17 Lasagna. "The Biological Revolution: Commercialization of the Molecule," reprint and issue of Research Management Review, Vol. 1, No 2, Fall 1987.

13:18 Correspondence related to "The Biological Revolution: Commercialization of the Molecule," MS and TS, April 1987 - April 1988, and n.d.


BOX 14: Ethics; General Principles; Obesity; and Over the Counter

Folder:
Ethics:

14:1 Lasagna. "Does the Public Need protection from Itself?," MS, TS, and PC from Clinical Therapeutics, Vol 9, No. 3, 1987.

14:2 Letter, Betsy Morris to Frank X. Blisard, regarding references for Lasagna's article, "Does the Public Need protection from Itself?," TS, March 19, 1987.

14:3 Lasagna. "The Desire To Regulate: The Wish To Discover," TS with MS editing, n.d.

14:4 Lasagna. "The Desire To Regulate: The Wish To Discover," proofs, December 1986 and n.d.

14:5 Letter, from Bioscience Ediprint to Lasagna, with Lasagna's MS notes, TS, January 6, 1987 [letter date].

14:6 Lasagna. "The Role and Responsibility of Industry In Research," TS and PC of publication [Drugs for Human Life Conference), n.d. [October 24, 1986].

14:7 Reprint order form for "The Role and Responsibility of Industry In Research," PC

14:8 Lasagna. "The FDA, Generic Drugs, and Psychiatry," TS and PC of article in The Psychiatric Times, March 1988; and with letter from Lasagna to publisher, December 30, 1987.

14:9 Lasagna. "Moral Decisions: The Search for an Ethical Policy on Allocating Health Care," January/February 1991, proof and PC of article in The Sciences, January/February 1991.

General Principles:

14:10 Lasagna and Victor G. Laties. "Problems Involved In The Study Of Drug-Modified Behavior In Normal Humans," [Prepared for Conference on the Evaluation of Pharmacotherapy in Mental Illness, Washington DC, September 19-22, 1956], TS, 18 pgs.

14:11 Lasagna. "Appendix III: Correlation of Clinical Effects With Blood Levels of Drugs," [presented at Symposium on the Physiological Equivalence of Drug Dosage Forms, Ottawa, Canada, June 27, 1969], TS, 10 pgs.

14:12 Dengler, Hans J. and Louis Lasagna. "Report of a Workshop on Fixed-Ratio Drug Combinations," European Journal of Clinical Pharmacology, 8, 1975, pgs. 149-154.

14:13 Lasagna. "Decision Processes in Establishing The Efficacy and Safety of Psychotropic Agents," [source unidentified, n.d.], PC, pgs. 29 - 50.

14:14 "Principles" lectures, lecture notes, 1982.

14:15 "Dose-Response" lecture, MS, n.d.

14:16 Tables about drug studies, TS, n.d., 12 pgs.

14:17 Venulet, Jan. "Towards Social Pharmacology," PC of TS, 14 pgs.

14:18 [Therapeutic Substitution] Letter from William Edmudson and portions of Private Practice, September 1983.

14:19 Soyka, Lester F. and Donald R. Mattison. "Prescription Drugs That Affect Male Sexual Function," Drug Therapy, august 1981, PC, pgs. 60 - 76; with TS; with 2 letters, TS, Soyka to Lasagna, August 14, 1981 and Lasagna to Richard Miller, January 25, 1982 [reply in MS]; and MS notes, n.d.,1 pg.

14:20 Miscellaneous TS pages [topics: drug interaction, acetylcholine receptors, drug transport, drug elimination, and a pharmacologist rhyme].

14:21 Advertisement for "Placebin," National Lampoon (" Medicine: The Nation's Number One Killer"), May 1975, [see pg. 106].

Hypnotics: [See also "Sedative and Hypnotic Poisoning"]

14:22 Lasagna articles:

  • Sundaresan, P.P. et al. "Methodology for Demonstrating Sustained Efficacy of Hypnotics: A Comparative Study of Triazolam and Flurazepam," [reprinted from] Clinical Pharmacology and Therapeutics, 25:4, April 1979.
  • Lasagna."The Halcion Story: Trial By Media" The Lancet, April 12, 1980, pg. 815 - 816.
  • "Drugs and Insomnia," Consensus Development Conference Summary, 4:10, n.d.

 


14:23 Lectures, Nursing 214, lecture notes and diagrams, 1983-1984.

14:24 MS notes

Obesity: [See also 17:2 "Vitamins and Nutrition"]

14:25 Lasagna. "The Pharmacotherapy of Obesity," TS with MS editing, TS, proof with attached correspondence and MS notes, PC of Psychopharmacology: The Third Generation of Progress, Chapter 134, pgs. 1281 -1284, with miscellaneous related materials, 1985 - 1987.

Over The Counter: [Continued in next box]

14:26 "Proposed OTC Drug Categories For Review," TS, n.d.; "The PA Views OTC's - or - What's in Store of OTC's in the Future," by Joseph M. Pisani

Ad Hoc Committee Meeting on "OTC Drugs," October 14 - 15, 1971.

14:27 "Current Research Methodology in the Evaluation of Proprietary Medicines - II," December 65, 1972.


BOX 15: Over the Counter; Pain Medication; Pharmacology; Prescribing; Prisoner Research; Rodale Press Case; and Sedative & Hypnotic Poisoning.

Folder:
Over The Counter: [Continued from previous box]

15:1 Proprietary Association, Research & Scientific Development Conference, December 9, 1976.

Pain Medication:

15:2 Lasagna. "What Are the Properties of an Ideal Pain Medication," TS, article in Medical Dialogue, and related correspondence, 1987.

Pharmacology:

15:3 "Pharmacology 500":

 

  • Lasagna. "Principles," questions, TS, n.d. 3 pgs.
  • DiStefano, V. "Receptors," outline, TS, n.d., 3 pgs.
  • DiStefano, Victor. "Major pathways for drug biotransformations other than conjugation," handout, February 4, 1977.
  • Edwards, John. "Pharmacogenetics," TS, n.d


Prescribing:

15:4 Prescribing lecture, notes and articles used in preparation [?]

Prisoner Research:

15:5

  • Letters and Ad Hoc Committee report, September 8, 1981
  • Blackwell B. and Frank J. Ayd, Jr. "Problems in the Evaluation of a New Antidepressant Drug in Prison Volunteers," [reprinted from] The Journal of Clinical Pharmacology, 11:1, January-February, 1971, pgs. 19 - 26.
  • Weissman, Lester, et al. "Motivation and the Prisoner Volunteer: A Preliminary Report," The Journal of Clinical Pharmacology, February - March 1972, pgs. 97 - 100.
  • McMahon, F. Gilbert. "The 'Normal' Prisoner in Medical Research," The Journal of Clinical Pharmacology, February - March 1972, pg. 71 -73.


Rodale Press Case:

15:6 Correspondence, Robert Rodale and Louis Lasagna, TS, September 1964, [2 letters]

15:7 Letter, Robert Rodale to Lasagna, with witness testimony enclosed, TS, October 9, 1964.

15:8 Letter, Robert Rodale to Lasagna, with enclosures, TS, November 20, 1964.

15:9 "United States of America Before Federal Trade commission", legal document, TS, n.d.36 pgs.

15:10 Official Transcript of proceedings, December 8, 1964, pgs. 538-568.

15:11 "Statement of Louis Lasagna, M.D...." TS, n.d., 8 pgs.

15:12 [Lasagna]. "An Analysis of' 'The Health Finder' by J.I. Rodale," TS, n.d., 6 pgs. [2 copies].

15:13 Rodale, Robert, Ed. Health Bulletin, 2:35, September 12, 1964.

15:14 Rodale, J.I. How To Eat For A Healthy Heart, This Pace Is Not Killing Us, Rodale Books, 1954.

15:15 Lasagna articles:

  • "Across-The-Counter Hypnotics: Book, Hazard, Or Fraud?" [reprinted from] Journal of Chronic Diseases, 4:5, November 1956.
  • "The Diseases Drugs Cause," [reprint from] Perspectives in Biology and Medicine, 7:4, Summer 1964.
  • " A Matter of Perspective," [reprint from] Journal of Chronic Diseases, Vol 15, 1962, pgs 3-5.

 


15:16 Ladimer, Irving. "The Moral and Legal Responsibilities of the Writer of Health Articles," [presented at the Medical Writers Institute, September 25, 1995], TS.

15:17 Articles by other authors:

 

  • [author unidentified] "Boric Acid - Toxic and Useless," Medical Tribune, August 10, 1964, PC [2 copies]
  • [Review of] Louis Goodman's "The Pharmacological Basis of Therapeutics" [source unidentified, n.d.], PC.
  • Kelly, Michael. "Steroids: Drugs of Addiction To Patient And Doctor," Journal of Chronic Diseases, Vol 17, 1964, PC, pp. 461 - 464.
  • The Medical Letter, 6:19, September 11, 1964, PC, pgs 73 - 75 [2 copies].


Sedative & Hypnotic Poisoning:

15:18 Notes on coma routine and treatment for poisonings, TS, n.d.


BOX 16: SMON Lawsuit; Sleep; "Sore Throat;" "Tampa Case;" Taste; and Tranquilizers.

Folder:
SMON Lawsuit:

16:1 Materials related to SMON lawsuit, 1972 - 1979.

Sleep:

16:2 Articles by Lasagna: [arranged alphabetically by title]

  • Imboden, John and Lasagna. "An Evaluation Of Hypnotic Drugs In Psychiatric Patients," [reprinted from] Bulletin Of The John Hopkins Hospital, 99:2, pgs. 91-100, August 1956.
  • Lasagna. "The Newer Hypnotics," [reprinted from] The Medical Clinics of North America, March 1957, pgs. 359 - 368.
  • Von Felsinger, John M., Lasagna, Henry R. Beecher. "The Persistence of Mental Impairment Following A Hypnotic Dose Of A Barbiturate," [reprinted from] The Journal of Pharmacology and Experimental Therapeutics, 109:3, November 1953, pgs, 284 - 291.
  • "The Pharmacological Basis For The Effective Use Of Hypnotics," 1:2. February 1967.

 


16:3 Articles by others: [arranged alphabetically by last name of author]

 

  • Freeman, Frank R. "Clinical Pharmacology of Sleep," TS, 29 pgs.
  • Goulding, R. "Methaqualone" [condensed by Eliot D. Hutchinson], Special Topics,14:5, September 1970, pg. 15.
  • Haider, Ijaz. "Patterns Of Insomnia In Depressive Illness: A Subjective Evaluation," [reprint from] The British Journal of Psychiatry, 114:514, September 1968.
  • Hinton, J.M. "A Comparison Of The Effects Of Six Barbiturates And A Placebo On Insomnia And Motility In Psychiatric Patients," [Reprinted from] British Journal of pharmacology and Chemotherapy, 20:2, 1963, pgs. 319 -325.
  • Kales, Anthony and Joyce D. Kales. Sleep Laboratory Evaluation OF Psychoactive Drugs, 4:9, September 1970 [and PC].
  • Kinnard, William J. "A Preliminary Procedure For The Evaluation Of Central Nervous System Depressants," Journal of Pharmacology and Experimental Therapeutics, 121:354, November 1957.
  • Kim, Robert K.S. "The Experimental Evaluation Of Sedative Agents In Animals," [reprinted from] Annals of The New York Academy of Sciences, 64:4, pgs. 667-678, November 16, 1956, pgs. 667 - 677.
  • Miller, Lloyd C. "Hazards of Paradehyde," Pharmacopedia Of The United States of America, Vol 21, October 1964; with letter Louis Lasagna to Henry Derewicz [chief pharmacist, The John Hopkins University, TS September 10, 1965.
  • Salter, C.E. "Thalidomide: Clinical Trial of a New Hypnotic Drug," [reprinted from Journal of Clinical And Experimental Psychopathology & Quarterly Review of Psychiatry and Neurology, 20:3, July-September 1959., pgs, 243 -246.
  • Teehan et al. [condensed by James Edward Huff]. "Acute Ethchlorvynol (Placidyl) Intoxication," Special Topics, 15:1, May 1971, pg. 9 - 12.
  • [author unidentified] "Sleep," The Lancet, pg. 82; with attached MS notes.

 


16:4 Letter, John Hinton to Louis Lasagna, MS, May 6, 1961; with "A Comparison Of The Effects Of Six Barbiturates And A Placebo On Insomnia And Motility In Psychiatric Patients," [Reprinted from] British Journal of Pharmacology and Chemotherapy, 20:2, 1963, pgs. 319 -325.

16:5 Letter and draft of proposed "General Considerations Concerning Guidelines For Clinical Evaluation of Drugs," PMA Special Committee, TS, November 2, 1970.

16:6 "General Class Exercises," November 3, 1970, TS.

16:7 Application, Donald R. Goodenough, Research Career Award Program, U.S. Department of Health Sleep, and Welfare, April 27, 1962.

"Sore Throat " [use of antibiotics to treat "minor" respiratory illnesses]:

16:8 Letters [responses to Lasagna's open letter March 27, 1974, in the Medical Tribune November/December 1975; arranged alphabetically by last name of correspondent]

 

  • Baker, Colin [to Arthur M. Sackler], PC of TS, December 8, 1975.
  • Bodner, Stanley J., TS, December 1, 1975.
  • Castaldo, Louis F., TS, December 7, 1975.
  • Cooper, Jules, TS, November 23 1975, November 14, 1975, and December 15, 1975.
  • DiPolala, Joseph, TS, January 7, 1976.
  • Ganelin, Robert S., TS, November 21, 1975.
  • Guazzo, Eugene, TS, November 13, 1975.
  • Heiney, Zelda E., TS, November 18, 1975.
  • Hillyear, Peter N., TS, 1975
  • Manning, Ephrain L, MS, November 20, 1975.
  • Mardock, Julian, TS, n.d.
  • Michael, Sidney R., TS, November 13, 1975.
  • Patch Peter E., TS, December 2, 1975.
  • Peterson, Francis K.D, Jr., TS, November 18, 1875
  • Potts, C.R., TS, December 2, 1975.
  • Reimann, Hobart A., TS, November 14, 1975.
  • Reynolds, Jeffery C., TS, December 15, 1975.
  • Slater, Stan, TS, December 9, 1975.
  • Van der Weken, D. William., TS, December 2, 1975.
  • Young, J. Melvin Young, MS, n.d.
  • [Unidentified], MS, March 15, 1976.

 


16:9 "Medical Record for Peter Lasagna," [study of treatment development of minor respiratory illness], MS, February 1976.

16:10 "The Value of Antibiotics in Minor Respiratory Illness In Children: A Controlled Trial," Extract from The Medical Journal of Australia, March 2, 1974.

"Tampa Case":

16:11 TS related to the case of Wilma Lucille Witt, who left her estate to a hospital.

Taste:

16:12 notes, MS, n.d.

Tranquilizers:

16:13 MS notes, correspondence, and articles related to tranquilizers.

16:14 "Major Tranquilizers I," Typescripts, MS notes, articles. 1978 - 1980

16:15 "Major Tranquilizers II," Typescripts and MS notes, n.d.

16:16 "Minor Tranquilizers I," articles, typescripts, MS notes; including the following articles by Lasagna:

 

  • "Benefit-Risk in the Use of Benzodiazepines," TS, n.d
  • "The Halcion Story: Trial By Media," PC of Lancet proof
  • Introduction to "How Useful is Drug Therapy for Senile Dementia?"

 


16:17 "Minor Tranquilizers II," correspondence and diagrams, 1979 - 1982


BOX 17: Vitamins and Miscellaneous / Other

Folder:
Vitamins:

17:1 Vitamin C, Typescript, MS notes, articles, and correspondence, 1971 - 1977.

17:2 Vitamins and Nutrition, MS notes, typescripts, avadavat, and articles; including the following articles by Lasagna:

 

  • "Introduction," TS with MS editing
  • "Drug Therapy," TS with MS editing
  • "The Use of Drugs in the Treatment of Obesity," TS


Miscellaneous / Other:

17:3 TS and articles by Lasagna:

  • "Commentary" [cardio-renal], 4 TS, n.d.
  • "Keynote Address," Designs to Achieve Category I, [Proceedings of the 1976 Research and Scientific Development Conference]

 


17:4 "Reflections on 25 Years of P&T: An Interview with David Nash, MD, MBA, and Louis Lasagna," Sonja Sherritze, P&T, Vol 26, No. 12, December 2001, pg. 605 - 612.

17:5 Miscellaneous correspondence, 1975 - 1979.

17:6 Lists

 

  • "Drugs Not To Be Taken By Patient"
  • "Consumer Trends & Expenditures"

 


17:7 Articles


BOX 18: Audiocassette Tapes

Margaret Mead, Rochester University, May 18, 1976, 1 tape.

OHE Conference, London, June 15, 1976, 1 tape.

HEW Panel Review, March 28, 1977, 3 tape.

DOBELLE VISIT - Devices, December 22, 1980, 1 tape.

Pfizer meeting, New York City, June 10, [----?], 2 tapes.

Olsen, n.d., 2 tapes

NAE Tim Thomas visit, December 11, 1980, 2 tapes.


BOX 19: Video Tapes

University of Rochester, Pharmacology, Medical, and Toxicology theater productions [written, directed, and starring Louis Lasagna], 1972 - 1984:

"Drugs on Trial," 1972, 95 minutes. [Note: "LL as lawyer defending negotiations on drugs"].

"FDA Hearing," 1973, 90 minutes. [Note: "mock senate hearing with LL as a southerner with pince nez"; "Bill Wardell on this"].

"Senate Hearing," 1974, 95 minutes.

"The OZ Connection," 1975, 75 minutes.

"Star Drek," 1976.

"Up Yours - Down Yours," 1977.

"Phunny Pharm Awards," 1978.

"U of R Through The Ages," 1979. [note: "LL as 2000 year old man; " "Mike Wenefrouls"]

"Medivision - Now That's Incredible," 1980. [Note: "LL sings"]

"Elmwood Ave. Blues," 1982 , 97 minutes.

"The Frankies," 1983.

"After G*A*S*H," second year show, edited master, 1984. [Note: 'Louie -Louie' + long obit 0-1.57"].

"The PhRMA Foundation Award in Excellence 2001 - Dr. Louis Lasagna," November 27, 2001.

"Medical English - Part I," Executive Producer: Rosemarie Van Camp, n.d. 24 mins.

"Medical English - Part II," Executive Producer: Rosemarie Van Camp, 19:30. [Note: "LL in beginning walking [?]& presenter (1993?)"].

""Medical English - Part III," Executive Producer: Rosemarie Van Camp," 20:00. [Note: "LL with 'patient' (1993?)"].

"FDA, Past, Present, And Future," Louis Lasagna, R&D Informs, July 3, 1990. [Note: "LL is on this one - a talk. Quality is so-so. CSDD History on first part; 'Marion' talk'].

"Video Highlights of The Future of The Pharmaceutical Industry, 1991 Symposium," [Note: "Competitions: LL comments/discussant"].

"G.D. Searle Talk," Louis Lasagna, March 7, [19]91. [Note: "Nice quote in this one about being impartial (tape stopped there) Also: 'It's a perfectly good question, but I don't have the brains to answer it.' Very big smile"; )-1.33 (.0-.33) on impartiality"].

"Drug Prices," June 3, 1993 [Note: "LL: In his office 30 secs ... good quality, but he does not look well."]

"Dedication: Center of Toxicology", guest speaker: Margaret Mead, tape 1, n.d.

"Dedication: Center of Toxicology", guest speaker: Margaret Mead, tape 2, n.d.

"Margaret Mead at Whipple Auditorium," May 18, [19]76, edited copy, 16:00, audio: channel 1 and 2].

[Unidentified], WHEC TV, Rochester, NY, n.d.

""The Pill," National Film Board of Canada," 44 minutes.